Isabella Russo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3794406/publications.pdf

Version: 2024-02-01

83 papers	3,068 citations	126907 33 h-index	175258 52 g-index
84 all docs	84 docs citations	84 times ranked	4607 citing authors

#	Article	IF	Citations
1	p140Cap Controls Female Fertility in Mice Acting via Glutamatergic Afference on Hypothalamic Gonadotropin-Releasing Hormone Neurons. Frontiers in Neuroscience, 2022, 16, 744693.	2.8	0
2	Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis. Antioxidants, 2022, 11, 569.	5.1	8
3	PCSK9 Biology and Its Role in Atherothrombosis. International Journal of Molecular Sciences, 2021, 22, 5880.	4.1	70
4	Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus. International Journal of Molecular Sciences, 2021, 22, 7032.	4.1	5
5	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. International Journal of Molecular Sciences, 2021, 22, 7193.	4.1	26
6	Prothrombotic Phenotype in COVID-19: Focus on Platelets. International Journal of Molecular Sciences, 2021, 22, 13638.	4.1	21
7	Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 282-291.	2.6	44
8	Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia. International Journal of Molecular Sciences, 2020, 21, 4983.	4.1	10
9	Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-12.	4.0	19
10	Influence of Cardiometabolic Risk Factors on Platelet Function. International Journal of Molecular Sciences, 2020, 21, 623.	4.1	66
11	In-Silico Transcriptome Analyses of Hemostasis Triggers in Inflamed Vs Normal Mucosa of IBD Patients. Blood, 2020, 136, 19-20.	1.4	0
12	Nuclear-cytoplasmic Shuttling in Chronic Myeloid Leukemia: Implications in Leukemia Maintenance and Therapy. Cells, 2019, 8, 1248.	4.1	3
13	Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin. Thrombosis Research, 2019, 180, 74-85.	1.7	8
14	Transferrin Saturation Inversely Correlates with Platelet Function. Thrombosis and Haemostasis, 2019, 119, 766-778.	3.4	4
15	p140Cap Regulates GABAergic Synaptogenesis and Development of Hippocampal Inhibitory Circuits. Cerebral Cortex, 2019, 29, 91-105.	2.9	13
16	Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. BioMed Research International, 2018, 2018, 1-11.	1.9	50
17	Cardioprotective Properties of Human Platelets Are Lost in Uncontrolled Diabetes Mellitus: A Study in Isolated Rat Hearts. Frontiers in Physiology, 2018, 9, 875.	2.8	18
18	Effects of a 8-week treatment with monoclonal antibody anti-PCSK9 therapy on platelet function in subjects affected by familial hypercholesterolemia. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, e7-e8.	2.6	0

#	Article	IF	Citations
19	The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. Nature Communications, 2017, 8, 14797.	12.8	26
20	Effects of PCSK9 inhibitors on platelet function in adults with hypercholesterolemia. Atherosclerosis, 2017, 263, e30-e31.	0.8	6
21	Platelets, diabetes and myocardial ischemia/reperfusion injury. Cardiovascular Diabetology, 2017, 16, 71.	6.8	73
22	Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. Thrombosis and Haemostasis, 2017, 117, 1115-1128.	3.4	61
23	In Type 2 Diabetes mellitus the GLP-1 effects on platelets are impaired. Atherosclerosis, 2016, 252, e257-e258.	0.8	2
24	LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate. Molecular Neurodegeneration, 2016, 11, 1.	10.8	128
25	Leucineâ€rich repeat kinase 2 interacts with p21â€activated kinase 6 to control neurite complexity in mammalian brain. Journal of Neurochemistry, 2015, 135, 1242-1256.	3.9	57
26	Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-ÎºB p50 signaling in cultured microglia cells. Journal of Neuroinflammation, 2015, 12, 230.	7.2	99
27	Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies. Medicinal Research Reviews, 2015, 35, 968-1031.	10.5	43
28	LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Frontiers in Molecular Neuroscience, 2014, 7, 49.	2.9	82
29	A Short-Term Incubation with High Glucose Impairs VASP Phosphorylation at Serine 239 in response to the Nitric Oxide/cGMP Pathway in Vascular Smooth Muscle Cells: Role of Oxidative Stress. BioMed Research International, 2014, 2014, 1-9.	1.9	5
30	A novel truncated form of eNOS associates with altered vascular function. Cardiovascular Research, 2014, 101, 492-502.	3.8	17
31	LRRK2 and neuroinflammation: partners in crime in Parkinsonâ€™s disease?. Journal of Neuroinflammation, 2014, 11, 52.	7.2	148
32	Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiology of Disease, 2014, 71, 62-73.	4.4	48
33	Leptin and Vascular Smooth Muscle Cells. Current Pharmaceutical Design, 2014, 20, 625-634.	1.9	30
34	AMPA Receptor Properties are Modulated in the Early Stages Following Pilocarpine-induced Status Epilepticus. NeuroMolecular Medicine, 2013, 15, 324-338.	3.4	33
35	Oleic Acid Increases Synthesis and Secretion of VEGF in Rat Vascular Smooth Muscle Cells: Role of Oxidative Stress and Impairment in Obesity. International Journal of Molecular Sciences, 2013, 14, 18861-18880.	4.1	11
36	Modulation of dendritic AMPA receptor mRNA trafficking by RNA splicing and editing. Nucleic Acids Research, 2013, 41, 617-631.	14.5	35

#	Article	IF	Citations
37	Effects of High Glucose on Vascular Endothelial Growth Factor Synthesis and Secretion in Aortic Vascular Smooth Muscle Cells from Obese and Lean Zucker Rats. International Journal of Molecular Sciences, 2012, 13, 9478-9488.	4.1	14
38	The Prothrombotic Tendency in Metabolic Syndrome: Focus on the Potential Mechanisms Involved in Impaired Haemostasis and Fibrinolytic Balance. Scientifica, 2012, 2012, 1-17.	1.7	34
39	3,6â€²â€Dithiothalidomide, a new TNFâ€Î± synthesis inhibitor, attenuates the effect of AÎ²_{1â€“42} intracerebroventricular injection on hippocampal neurogenesis and memory deficit. Journal of Neurochemistry, 2012, 122, 1181-1192.	3.9	61
40	Tumor necrosis factor-Î± synthesis inhibitor 3,6â€²-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimerâ€™s disease. Journal of Neuroinflammation, 2012, 9, 106.	7.2	179
41	High Glucose Inhibits the Aspirin-Induced Activation of the Nitric Oxide/cGMP/cGMP-Dependent Protein Kinase Pathway and Does Not Affect the Aspirin-Induced Inhibition of Thromboxane Synthesis in Human Platelets. Diabetes, 2012, 61, 2913-2921.	0.6	27
42	Effects of neuroinflammation on the regenerative capacity of brain stem cells. Journal of Neurochemistry, 2011, 116, 947-956.	3.9	135
43	Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: Influence of insulin resistance and oxidative stress. Atherosclerosis, 2011, 216, 44-53.	0.8	40
44	Cyclooxygenase-1 is involved in the inhibition of hippocampal neurogenesis after lipopolysaccharide-induced neuroinflammation. Cell Cycle, 2011, 10, 2568-2573.	2.6	36
45	AMPA Receptor Regulation at the mRNA and Protein Level in Rat Primary Cortical Cultures. PLoS ONE, 2011, 6, e25350.	2.5	36
46	In Central Obesity, Weight Loss Restores Platelet Sensitivity to Nitric Oxide and Prostacyclin. Obesity, 2010, 18, 788-797.	3.0	59
47	The Old and the New in the Treatment of Type 2 Diabetes: Focus on the Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Metformin. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S3420.	0.4	1
48	Adipocytokines in Atherothrombosis: Focus on Platelets and Vascular Smooth Muscle Cells. Mediators of Inflammation, 2010, 2010, 1-26.	3.0	55
49	The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus. Current Vascular Pharmacology, 2010, 8, 327-337.	1.7	59
50	Role of NMDA receptor in homocysteine-induced activation of Mitogen-Activated Protein Kinase and Phosphatidyl Inositol 3-Kinase pathways in cultured human vascular smooth muscle cells. Thrombosis Research, 2010, 125, e23-e32.	1.7	26
51	Platelet dysfunction in central obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 440-449.	2.6	117
52	Contribution of insulin resistance to vascular dysfunction. Archives of Physiology and Biochemistry, 2009, 115, 199-217.	2.1	34
53	Sodium azide, a bacteriostatic preservative contained in commercially available laboratory reagents, influences the responses of human platelets via the cGMP/PKG/VASP pathway. Clinical Biochemistry, 2008, 41, 343-349.	1.9	14
54	Resistance to the Nitric Oxide/Cyclic Guanosine 5â€²-Monophosphate/Protein Kinase G Pathway in Vascular Smooth Muscle Cells from the Obese Zucker Rat, a Classical Animal Model of Insulin Resistance: Role of Oxidative Stress. Endocrinology, 2008, 149, 1480-1489.	2.8	44

#	Article	IF	Citations
55	Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome. Current Vascular Pharmacology, 2008, 6, 313-328.	1.7	30
56	Platelet Resistance to the Antiaggregatory Cyclic Nucleotides in Central Obesity Involves Reduced Phosphorylation of Vasodilator-Stimulated Phosphoprotein. Clinical Chemistry, 2007, 53, 1053-1060.	3.2	32
57	Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use. Cardiovascular & Hematological Disorders Drug Targets, 2007, 7, 228-249.	0.7	23
58	Insulin activates hypoxia-inducible factor-1Î± in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. Diabetologia, 2006, 49, 1049-1063.	6.3	47
59	Sodium Azide in Commercially Available C-Reactive Protein Preparations Does Not Influence Matrix Metalloproteinase-2 Synthesis and Release in Cultured Human Aortic Vascular Smooth Muscle Cells. Clinical Chemistry, 2006, 52, 1200-1201.	3.2	7
60	Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States. Current Diabetes Reviews, 2006, 2, 409-430.	1.3	27
61	High glucose rapidly activates the nitric oxide/cyclic nucleotide pathway in human platelets via an osmotic mechanism. Thrombosis and Haemostasis, 2005, 93, 517-526.	3.4	20
62	C-reactive protein increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells. Translational Research, 2005, 146, 287-298.	2.3	35
63	Homocysteine rapidly increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells. Thrombosis and Haemostasis, 2005, 94, 1285-1293.	3.4	27
64	Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. European Journal of Clinical Investigation, 2004, 34, 482-489.	3.4	49
65	Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. European Journal of Clinical Investigation, 2004, 34, 664-673.	3.4	75
66	The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents. Thrombosis Research, 2004, 114, 265-273.	1.7	40
67	40th EASD Annual Meeting of the European Association for the Study of Diabetes. Diabetologia, 2004, 47, A1-A464.	6.3	41
68	Comparison between the effects of the rapid recombinant insulin analog Lispro (Lys B28, Pro B29) and those of human regular insulin on platelet cyclic nucleotides and aggregation. Thrombosis Research, 2003, 109, 323-327.	1.7	4
69	Platelet resistance to the antiaggregating effect of N-acetyl-l-cysteine in obese, insulin-resistant subjects. Thrombosis Research, 2003, 110, 39-46.	1.7	21
70	Insulin Stimulates Glucose Transport Via Nitric Oxide/Cyclic GMP Pathway in Human Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 2215-2221.	2.4	86
71	Insulin influences the nitric oxide cyclic nucleotide pathway in cultured human smooth muscle cells from corpus cavernosum by rapidly activating a constitutive nitric oxide synthase. European Journal of Endocrinology, 2002, 147, 689-700.	3.7	13
72	Adenosine increases human platelet levels of 3â€²,5â€²-cGMP through nitric oxide. Thrombosis Research, 2002, 105, 71-78.	1.7	75

#	Article	IF	Citations
73	Comparison between the effects of the rapid recombinant insulin analog aspart and those of human regular insulin on platelet cyclic nucleotides and aggregation. Thrombosis Research, 2002, 107, 31-37.	1.7	16
74	Catecholamines, via Î²-adrenoceptors, Increase Intracellular Concentrations of 3â€™,5â€™-cyclic Guanosine Monophosphate (cGMP) through Nitric Oxide in Human Platelets. Thrombosis and Haemostasis, 2002, 87, 539-540.	3.4	12
75	Catecholamines, via beta-adrenoceptors, increase intracellular concentrations of 3',5'-cyclic guanosine monophosphate (cGMP) through nitric oxide in human platelets. Thrombosis and Haemostasis, 2002, 87, 539-40.	3.4	4
76	Studies on Inhibition of Human Platelet Function by Sodium Nitroprusside. Kinetic Evaluation of the Effect on Aggregation and Cyclic Nucleotide Content. Thrombosis Research, 2001, 102, 319-330.	1.7	18
77	N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets. European Journal of Clinical Investigation, 2001, 31, 452-461.	3.4	39
78	l-Arginine Modulates Aggregation and Intracellular Cyclic 3â€²,5â€²-Guanosine Monophosphate Levels in Human Platelets. Thrombosis Research, 1999, 94, 307-316.	1.7	22
79	Influence of protamine on adhesion, chemotaxis and proliferation of human vascular smooth muscle cells. Diabetologia, 1997, 40, 67-75.	6.3	9
80	Nonenzymatic glycation of fibronectin impairs adhesive and proliferative properties of human vascular smooth muscle cells. Metabolism: Clinical and Experimental, 1996, 45, 285-292.	3.4	12
81	Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood. Thrombosis Research, 1995, 77, 399-410.	1.7	4
82	Insulin Stimulates the Polymorphonuclear Leukocyte Chemokinesis. Hormone and Metabolic Research, 1993, 25, 321-322.	1.5	11
83	Insulin, at Physiological Concentrations, Enhances the Polymorphonuclear Leukocyte Chemotactic Properties. Hormone and Metabolic Research, 1992, 24, 225-228.	1.5	29